NAYA Biosciences Inc
NASDAQ:NAYA
Gross Margin
NAYA Biosciences Inc
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
NAYA Biosciences Inc
NASDAQ:NAYA
|
21.9m USD |
42%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
218.8B USD |
56%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
175.4B USD |
67%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
148.4B USD |
68%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
141.5B USD |
64%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
115.9B USD |
66%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
66.8B USD |
45%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
57.9B EUR |
38%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
41.5B USD |
79%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
291.6B CNY |
64%
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
37.2B USD |
42%
|
NAYA Biosciences Inc
Glance View
INVO BioScience, Inc. is a fertility company. The company is headquartered in Sarasota, Florida and currently employs 25 full-time employees. The company went IPO on 2008-11-11. The Company’s initial pipeline includes two novel Flex-NK Bispecific Antibodies. NY-303: its GPC3-targeted FLEX-NK Bispecific Antibody for Hepatocellular Carcinoma (HCC). NY-338: its CD38-targeted FLEX-NK Bispecific Antibody for Multiple Myeloma (MM) & Autoimmune Diseases. Its lead GPC3-targeting FLEX-NK bispecific antibody is entering Phase I/II clinical trials and positioned as a monotherapy option to address the unmet needs of the of hepatocellular carcinoma (HCC) patients not responding to standard of care with checkpoint inhibitors. INVOcell is its novel, FDA-cleared and CE-marked intravaginal culture (IVC) device. The company offers a viable alternative to vitro fertilization (IVF) that uses the female body for fertilization and incubation, keeping women at the center of the reproductive process.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on NAYA Biosciences Inc's most recent financial statements, the company has Gross Margin of 42.4%.
You don't have any saved screeners yet